TruScreen ASX Small Caps Conference Presentation

TruScreen Group Ltd
NZX|ASX: TRU
A Growth Company
27 March 2024

Martin Dillon
CEO TruScreen

TruScreen Group Ltd
⚫TruScreen Group Ltd - ASX and NZX TRU - is a revenue generating company with annual
sales exceeding NZD $2m.
⚫The Revenue Model:
TruScreen manufactures and SELLS:
othe TruScreen Real Time Cervical Cancer Screening DEVICE and
othe TruScreen Disposable SINGLE USE SENSOR - a consumable product delivering
recurring revenue.
⚫For each patient screened with the TruScreen device a new Single Use Sensor must be
used.
⚫Two devices are manufactured - one made in China for use in China, where locally
products have preferential market access, and one made in Australia for other markets
2

Key
achievements
Sales growth
FY2024

Top achievements FY2024
Sales and Revenue FY2024:
2024 Sales expected to be > NZD $2m
Q1 – Q3 FY2024:
✓Consumable (Single Use Sensor) 22% growth YOY
✓Device sales 40% growth YOY
✓China, major contributor with immense market growth opportunity
4

5
*This is not a forecast of performance or expected results
0
50000
100000
150000
200000
250000
0
50
100
150
200
250
300
350
Mar '19Mar '20Mar '21Mar '22Mar '23Mar '24*Mar '25*
FY2019 - FY2023, actuals
FY2024 - FY025, projections*
Installed DevicesSUS Sales
we are here
Device installations and SUS sales FY2019- FY2025

Top achievements FY2024
6
Achievements:
✓China: COGA Blue Book and CSCCP Guideline entries
✓Vietnam: MOH inclusion in the National Technical List
✓Saudi Arabia: commercial roll out and private health insurerslisting

Top achievements FY2024
7
Achievements:
✓Zimbabwe: continues NAC screening program, TruScreen wins tenders
✓Poland: TruScreen wins top award for implementation in the largest public hospital
network for women health in Poland
✓Mexico: TruScreen receivesCofepris approval and access to public health sector

Top achievements FY2024
Achievements:
8
TruScreen Group Limited recently closed a NZD $2.6m rights issue and placement
confirming the markets confidence in our growth strategy.
Non Executive Chairman, Tony Ho commented, “this is an outstanding result and
demonstrated the confidence that investors have in the company”

About
TruScreen
technology

10
WORLD CLASS technology made simple
Real-time, AI-enabled, primary cervical cancer screening
device for detection of pre-cancerous and cancerous cervical
tissue
►Optical and electrical measurements painlessly detect abnormalities in
cervical tissue
►A Single Use Sensor (SUS) used for each exam, preventing cross-
contamination
►AI-enabled algorithm provides Normal/Abnormal
result immediately
►No invasive cervical cell or tissue collection
►EU certified (CE Mark) and ISO 13485 compliant
class IIa medical device

Trusted Clinical Performance
TruScreen
®
has been found
to be as sensitive in
detecting CIN2+ as
cytology**
4
TruScreen
®
has been
found to be more specific
in detecting CIN2+ as
cytology**
4
Over 40,000 women in
clinical trials to date***
* CIN2: A cervical biopsy finding that means moderately abnormal cells were found on the surface of the cervix.
CIN2 is usually caused by infection with certain types of human papillomavirus (HPV). Source: NIH, www.cancer.gov
** Data from large observational study, Cytology used was ThinPrep
*** Total number of subjects across published and unpublished clinical studies in English, data from TruScreen device generation I and II
11
11

TruScreen’s
Target
Markets

Cervical cancer is the fourth
most common cancer in
women globally
⚫Globally, 604000 new cases and 342 000 deaths
were recorded in 2020
⚫About 90% of these deaths occurred in low- and
middle-income countries
⚫The highest rates are inAfrica, Central America
and South-East Asia.
13
Source: Human papillomavirus and cancer (who.int)

14
European Union:
CE Mark
ISO 13485
Registered with:
✓TGA, Australia
✓MHRA, UK
✓NMPA, China
✓SFDA, Saudi Arabia
✓Roszdravnadzor,
Russia
✓COFEPRIS, Mexico
TruScreen’s presence and markets*
Mexico
10.7 M
119.1 M
13.4 M
Current Markets
Targeting commercial rollout
Markets under review
119.1 M
India
100.1 M
Indonesia
23.1 M
China
119 M
Saudi
3.6 M
CE
Europe
6.7 M
Vietnam
8.3 M
* Number of eligible women to undergo cervical cancer screening

China:
TruScreen’s largest market and
growth opportunity
●Over 300 million women of screening age,
with 113 million women needing to be
screened each year
●High government support for cervical cancer
screening
●Made in China TruScreen status from 2021 –
preferred market access in China

China:
TruScreen’s largest market and
growth opportunity
●Record sales of SUS: YTD FY24 results
exceeded total of FY23
●Roll out following inclusion of TruScreen in
COGA Blue Book and national CSCCP
nationalguidelines
●Growing Consumable (SUS) usage per
device

China, potential for SUS pull through growth
17
The devices in China
⚫currently have an average pull through
of 106 SUS per device per month,
24% growth in FY24
⚫the potential average pull-through of
SUS exceeds 290 per month
⚫Key accounts reach 500+ SUS pull
through
A B C D E F

18
December 2023, pipeline
•72 hospitals have obtained OBGYN
department acceptance, awaiting hospital
approval
•25 hospitals have received TruScreen
approval, awaiting tender completion
•12 tenders completed, awaiting hospital
installation
China, TruScreen FY2024 installations
By end of FY 2024
~100 devices
installed and in use
12
25
72

Vietnam
Focus market with renewed focus on public hospital rollout
The Market Opportunity
●24m women of screening Age
*
,

booming economy
and middle class
●No centralised screening programs
●Ministry Of Health (MOH) has listed TruScreen on
the National Technical List of approved technologies
●Strong local authorities support
*©2020 Precision Business Insights

Vietnam
Focus market with renewed focus on public hospital rollout
FY2024 Market Progress
Pipeline
●New legislation in Q1 FY 2025 to considerably
shorten approval process, accelerating new
installations
●2 main hospitals received MOH approval
●15 hospitals ready to apply to local authorities when
new approval process commences (expected Q1
FY25)
*©2020 Precision Business Insights

Zimbabwe
●Direct sales to Ministry of Health
●Very successful Government screening
program in Masvingo province, 14 000 women
screened to date,
●Two tenders won in 2023
Saudi Arabia
●Commercial rollout commenced in FY24
●Private Health Insurancereimbursement for
TruScreenfrom most PHIs.
FY24 Other Markets

Mexico
●COFEPRIS approval granted access to public
health sector
Poland
●TruScreen won top award in a Mother and
Child Institute challenge for healthcare
companies, granting implementation in the
largest public hospital network for women
health in Poland
FY24 Other Markets

Outlook strategy
and goals
FY2024-2025

Our Short Term Goals
24
Maximise
Seize the COGA
Blue Book &
CSCCP national
guideline window to
grow sales in China
Expand
Successfully expand
markets in
Zimbabwe, Saudi
Arabia, Vietnam and
ASEAN
Grow
Grow commercial
presence in Africa,
Middle East, Central
and Eastern Europe
Improve
Improve the gross
margin by reducing
COGS

Key take-aways
✓Sales growth from SUS consumable
usage driven by increased device
installed &use
✓China remains the biggest market with
huge opportunity
✓Global growth continues

©
www.truscreen.com

27
Martin Dillon
CEO
M - +61 449 115 065
E – martindillon@truscreen.com
TruScreen
36 Bradfield Road, CSIRO
Lindfield West NSW 2070
Australia
www.truscreen.com
Guy Robertson
Chief Financial Officer

M – +61 407 983 270
E – guyrobertson@truscreen.com
TruScreen
36 Bradfield Road, CSIRO
Lindfield West NSW 2070
Australia
www.truscreen.com
@TruscreenGroupLtd
@TruscreenGroupLimited

28

29
1.WHO, HPV and Cervical Cancer Fact sheet, 11 November 2020, https://www.who.int/news-
room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
2.WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), 2020
3.Human papillomavirus and cancer (who.int)
4.Wei, Y., Wang, W., Cheng, M., Hong, Z., Gu, L., Niu, J., Di, W., & Qiu, L. (2021). Clinical
evaluation of a real-time optoelectronic device in cervical cancer screening.European journal
of obstetrics, gynecology, and reproductive biology,266, 182–186.
https://doi.org/10.1016/j.ejogrb.2021.09.027.
5.Vet, J. N., Haindl, J. P., Velasquez, C., Parker, L. J., Burns, M. I., Morrell, S., & Campion, M.
J.. (2022). A Performance Evaluation of an Optoelectronic Cervical Screening Device in
Comparison to Cytology and HPV DNA Testing.European Journal of Gynaecological
Oncology,43(2), 213. https://doi.org/10.31083/j.ejgo4302027
6.Central Intelligence Agency, The World Fact Book, CHINA, People and Society, Female ages
25-64 Years, visited 28 August 2020, https://www.cia.gov/library/publications/the-world-
factbook/geos/ch.html
7.Central Intelligence Agency, The World Fact Book, VIETNAM, People and Society, Female
ages 25-64 Years, visited 28 August 2020, https://www.cia.gov/library/publications/the-world-
factbook/geos/vm.html
A world
without
cervical
cancer.